Emcure Pharmaceuticals Ltd (EMCURE)
₹1,881.00
Mkt cap
₹35,679 Cr
P/E ratio
37.70
P/B
7.21
Div yield
0.16%
ROE
20.10%
ROCE
24.00%
EPS (TTM)
₹49.89
Book value
₹261
52W range
1,272–1,925
Sector
Healthcare
Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally [1]
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−2.26% from high₹1,881
₹1,272+47.90% from low₹1,925
Current
₹1,881.00
Prev close
₹1,883.00
Day
−0.11%
Price performance
1D
−0.11%
1W
+1.06%
1M
+0.04%
3M
+14.89%
6M
+22.48%
1Y
+37.35%
YTD
+31.46%
Financials
FRevenue, profit & margin
P/E ratio
37.7×
EMCURE is 11% above the sector median of 34.0×
EMCURE37.7×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,556 | 1,663 | 1,668 | 1,771 | 1,815 | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | |
| Expenses | 1,261 | 1,334 | 1,374 | 1,460 | 1,479 | 1,621 | 1,608 | 1,714 | 1,684 | 1,794 | 1,871 | 1,990 | |
| Operating Profit | 296 | 329 | 294 | 311 | 336 | 381 | 355 | 402 | 417 | 475 | 493 | 480 | |
| OPM % | 19% | 20% | 18% | 18% | 19% | 19% | 18% | 19% | 20% | 21% | 21% | 19% | |
| Other Income | 15 | -2 | 22 | 12 | 23 | 36 | 4 | -6 | 0 | 3 | -36 | 14 | |
| Interest | 52 | 59 | 61 | 65 | 59 | 46 | 32 | 39 | 27 | 33 | 38 | 46 | |
| Depreciation | 67 | 70 | 84 | 91 | 94 | 97 | 97 | 97 | 99 | 105 | 105 | 106 | |
| Profit before tax | 191 | 198 | 171 | 167 | 207 | 273 | 230 | 261 | 291 | 341 | 314 | 341 | |
| Tax % | 26% | 26% | 30% | 27% | 26% | 26% | 32% | 24% | 26% | 26% | 26% | 29% | |
| Net Profit | 141 | 146 | 120 | 121 | 153 | 202 | 156 | 197 | 215 | 251 | 231 | 244 | |
| EPS in Rs | 7.21 | 7.69 | 6.27 | 6.36 | 7.95 | 10.29 | 8.11 | 9.97 | 10.92 | 12.84 | 12.16 | 12.84 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
6 Aug '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.47% · closed higher next day 2 of last 8
| Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|
| Broadcast | 13 Aug '24◦ | 8 Nov '24 | 6 Feb '25◦ | 22 May '25◦ | 7 Aug '25 | 11 Nov '25 | 4 Feb '26 | 5 May '26◦ |
| Earnings day | +0.54% | −3.19% | −5.64% | +9.99% | −1.52% | −3.99% | +1.91% | −1.82% |
| +1 day | +1.78% | −0.37% | −8.73% | +20.18% | −2.57% | −6.25% | −1.59% | −1.51% |
| +5 days | +9.92% | −9.35% | −22.61% | +13.89% | +2.29% | −4.63% | −0.49% | −1.97% |
| +15 days | +13.63% | −4.27% | −25.58% | +16.59% | −2.86% | −2.45% | −5.01% | +2.07% |
| +30 days | +15.81% | −1.33% | −21.69% | +7.25% | −7.40% | −0.01% | −2.35% | +3.72% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202677.83%Promoter
Promoters77.83%0.04
FIIs4.87%1.52
DIIs8.46%2.36
Public8.84%3.85
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Emcure Pharma | ₹1,881.00 | 37.73 | 35,679 | 0.16% | 244 | +21.01% | 2,470 | +16.70% | 23.97% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports1
Concall transcripts17
Credit ratings6
Announcements5
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Update On Completion Of Acquisition Of Shares Of Gennova Biopharmaceuticals Limited. 2d - Emcure completed acquisition of 12.05% Gennova stake for Rs 2,318.7 million, making Gennova wholly owned on July 21, 2026.Announcement under Regulation 30 (LODR)-Change in Management 21 Jul - Mr. P.S. Jayakumar completes second independent director term, ceasing July 21, 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 20 Jul - Emcure’s Poviztra received CDSCO approval for MASH treatment in adults with F2-F3 liver fibrosis.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Jul - Emcure Pharmaceuticals schedules Q1 FY27 earnings call on August 6, 2026 at 4:00 p.m. IST.Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30, 2026 15 Jul - Board meets August 6, 2026 to approve Q1 FY27 unaudited standalone and consolidated results.